How should hypervitaminosis D be managed?

Management of Hypervitaminosis D

Immediately discontinue all vitamin D supplementation and initiate aggressive intravenous hydration as first-line therapy, followed by bisphosphonates (zoledronic acid or pamidronate) for severe hypercalcemia (≥3.5 mmol/L or 140 mg/L), with treatment tailored to the degree of hypercalcemia and renal function.

Immediate Interventions

Discontinue Vitamin D Sources

• Stop all forms of vitamin D immediately - this includes prescription vitamin D, over-the-counter supplements, multivitamins, and any dietary supplements that may contain undeclared vitamin D 1
• Review all medications and supplements carefully, as manufacturing errors have resulted in products containing up to 425,000 IU per serving despite not claiming vitamin D content 2
• Investigate potential sources including protein supplements, creatine products, and natural health products 2

Hydration Therapy

• Intravenous saline is first-line treatment for symptomatic or severe hypercalcemia while awaiting effects of antiresorptive drugs 3, 4
• Volume expansion should be adapted to cardiac and renal function during the first 24 hours and continued according to calcium levels 3
• For patients in conventional care units, decide between oral and IV hydration based on calcium concentrations, age, and comorbidities 3

Severity-Based Treatment Algorithm

Severe Hypercalcemia (Calcium ≥3.5 mmol/L or 140 mg/L)

Admission and Monitoring:

• Admit to critical care unit if severe clinical manifestations present: altered consciousness, dehydration with acute renal failure, threatening ECG signs, or significant cardiovascular comorbidities 3
• Otherwise admit to conventional care unit based on symptoms and comorbidities 3

Pharmacological Treatment:

• Administer IV bisphosphonates after obtaining calcium and PTH samples 3
• Zoledronic acid or pamidronate are recommended unless contraindicated (e.g., pregnancy) 3
• Doses must be adjusted for renal function:
  • For creatinine clearance <60 mL/min: administer zoledronic acid over 30-60 minutes or pamidronate over 2-24 hours 4
• Calcitonin can be used as adjunctive therapy for rapid calcium reduction 2
• Denosumab is second-line for severely impaired renal function, insufficient first-line response, or bisphosphonate contraindications 3

Moderate Hypercalcemia (Calcium 2.54-3.5 mmol/L)

• Discontinue all vitamin D therapy if corrected total calcium exceeds 10.2 mg/dL (2.54 mmol/L) 1
• Initiate or intensify IV hydration
• Monitor calcium levels every 3 months minimum 1
• Consider bisphosphonates if symptoms develop or calcium continues rising

Mild Hypercalcemia with Elevated 25(OH)D

• Stop vitamin D supplementation immediately
• Implement low-calcium diet 2
• Ensure adequate hydration
• Monitor calcium and 25(OH)D levels regularly (may require months of monitoring) 2

Special Populations and Considerations

Patients with Renal Insufficiency

• Assess renal function (creatinine clearance or eGFR) before IV bisphosphonates 4
• Adjust bisphosphonate dosing for renal function 3, 4
• Consider denosumab as alternative in severe renal impairment 3
• Monitor for worsening renal function, as IV bisphosphonates can exacerbate kidney injury 4

Pediatric Patients

• Avoid single doses exceeding 300,000 IU in infants due to high hypercalcemia risk 5
• Use IV hydration, calcitonin, and pamidronate for severe cases 2, 6
• Maintain low-calcium diet during recovery 2
• Monitor for months after exposure as 25(OH)D has prolonged half-life 2

Patients with Granulomatous Disorders or Lymphoma

• These patients produce 1,25(OH)2D in unregulated fashion, causing hypercalciuria and hypercalcemia 5
• Target 25(OH)D levels of 20-30 ng/mL to prevent metabolic bone disease while avoiding hypercalcemia 5
• Serial monitoring of both 25(OH)D and calcium levels is essential 5
• Hypercalcemia typically occurs when 25(OH)D exceeds 30 ng/mL in these patients 5

Genetic Causes (CYP24A1 Mutations)

• Consider in patients with PTH-independent hypercalcemia, hypercalciuria, and elevated/high-normal 1,25(OH)2D 7
• Management includes avoiding vitamin D oversupplementation and excessive sun exposure 7
• Bisphosphonates useful for managing hypercalcemia 7
• Ketoconazole, fluconazole, or rifampicin are potential therapeutic options 7

Monitoring Requirements

Acute Phase

• Serum calcium: Daily until stable, then every 3 months minimum 1
• Serum phosphorus: Monitor and replete if low 4
• Serum magnesium: Monitor and replete if low 4
• Renal function: Assess before and during bisphosphonate therapy 4
• 25(OH)D levels: Track decline over months (long half-life) 2

Long-term Follow-up

• Continue monitoring calcium for months after exposure due to prolonged vitamin D half-life 2
• Maintain low-calcium diet until normocalcemia established 2
• Annual reassessment of 25(OH)D once normalized 1

Critical Pitfalls to Avoid

1. Do not restart vitamin D supplementation prematurely - 25(OH)D has a prolonged half-life and levels may remain elevated for months 2

2. Do not overlook undeclared vitamin D sources - manufacturing errors have resulted in massive vitamin D content in products not claiming to contain it 2

3. Do not use active vitamin D sterols (calcitriol, alfacalcidol) to treat 25(OH)D deficiency once toxicity resolves 8

4. Do not ignore dental health - monitor oral hygiene when using bisphosphonates or denosumab due to osteonecrosis of jaw risk 4

5. Do not forget to check vitamin D levels in family members if genetic causes suspected 7

6. Do not administer bisphosphonates without renal function assessment 4